SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scott_jiminez who wrote (4971)11/20/2001 9:03:46 AM
From: Biomaven  Respond to of 52153
 
NSAID/COX-2 inhibitors <-> neurodegenerative disease story

The lead article in this week's NEJM (not yet available on-line) is about this very issue. It concludes that long-term (cumulative use > 2 year) use of NSAIDs reduces Alzheimer incidence pretty dramatically, but not incidence of vascular dementia.

The other interesting area is statins and AD. Here ADRX has a patent, although I'm not sure what the practical consequences of that are. (ADRX will also benefit from increased use of NSAIDs via their Prilosec generic. <g>).

Peter



To: scott_jiminez who wrote (4971)11/20/2001 11:01:51 AM
From: twentyfirstcenturyfox  Respond to of 52153
 
Ron, O/T; for anyone interested in a novel alternative (transdermal/drug) to conventional NSAIDS products, check out Dimethaid, at dimethaid.com and its subsidiary, Oxo Chemie at oxochemie.com.
Oxo has the more interesting drug development - at Phase III (completed) but not announced. Cannot over-emphasize - do your DD here. Fox.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News